Deerfield Management

Ray Therapeutics is a company focused on developing innovative optogenetic gene therapies aimed at treating patients with blinding diseases. By creating technology that enhances the understanding of rare retinal conditions, the company strives to empower healthcare professionals to effectively diagnose, cure, and manage inherited retinal diseases. Through its commitment to advancing optogenetics, Ray Therapeutics seeks to improve the quality of life for those affected by these debilitating conditions.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

Operator of a biotechnology company intended for pioneering the development of genetic medicines for treating intractable diseases. The company specializes in developing genetic drugs by simultaneously engineering (Adeno-associated viruses) AAV capsids that bind to the human Transferrin Receptor 1 (TfR1) to enable intravenous delivery of therapeutics that use receptor-mediated transcytosis across the blood brain barrier allowing broad penetration of the central nervous system, and payloads to overcome limitations in cellular access, gene expression, pre-existing immunity and manufacturability, thereby enabling patients to treat debilitating diseases with limited options.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.

Lark Technologies, Inc. is a developer of a chronic disease prevention and management platform headquartered in Mountain View, California. Founded in 2010, the company provides the Lark application, which utilizes artificial intelligence alongside human coaching to deliver personalized, real-time support for individuals managing chronic conditions such as diabetes, prediabetes, and hypertension. The platform also integrates data on user activity, sleep, and nutrition to enhance health outcomes. Lark's programs, including its CDC-recognized Diabetes Prevention Program and Hypertension Program, have garnered around 1.5 million users and are backed by clinical evidence published in peer-reviewed journals. The company serves employers and health plans, aiming to deliver compassionate care at scale.

DeepSight Technology is a health technology company focused on enhancing diagnostic medical imaging through its innovative platform. Utilizing proprietary sensing technology, DeepSight combines patented hardware, software, and artificial intelligence to significantly improve image quality and extend the depth penetration of medical diagnostic ultrasounds. This advancement not only makes medical imaging safer, faster, and more affordable but also increases accessibility for healthcare providers. By offering cutting-edge sensor technology, DeepSight aims to broaden the capabilities of diagnostic ultrasounds, ultimately benefiting public health and well-being.

Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Operator of cardiovascular care delivery network intended to improve the quality and value of disease care. The company's platform facilitates building symbiotic relationships with health plans and primary care partners, along with an array of other capabilities including implementation of quality and process improvement efforts and technology-enabled care delivery among others, enabling clients to transition easily to value-based care.

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CarMax operates medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Cohere Health, Inc. is a software-as-a-service company based in Boston, Massachusetts, that focuses on enhancing the healthcare experience for patients, providers, and health plans. Incorporated in 2019, the company aims to improve the quality of care while reducing overall costs and increasing transparency throughout the patient care journey. Cohere Health specializes in intelligent prior authorization services, which are tailored to meet the specific needs of different health plans. By leveraging artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process and facilitates collaboration between physicians and health plans. This approach not only streamlines the utilization management service but also promotes quality care across the entire patient journey.

Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.

Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.

Curation Health, LLC offers a clinical decision support platform designed to facilitate the transition from fee-for-service to value-based care. Founded in 2018 and based in Annapolis, Maryland, the company provides a point-of-care solution that integrates with electronic health records to deliver actionable risk adjustment insights. This platform captures accurate clinical data before and after patient visits, ensuring comprehensive provider documentation. Curation Health's services enhance performance for various healthcare programs, including Medicare Advantage, MSSP, Medicaid risk programs, and quality initiatives based on standard measures. By leveraging clinical and quality rules, the platform aims to improve documentation processes and the overall value of patient care.

Reprieve Cardiovascular, Inc., a medical device company, develops and manufactures a medical fluid management device for congestive heart failure. It offers Reprieve technology, a fluid management therapy solution providing clinicians with the ability to precisely control a patient’s fluid volume for acute decompensated heart failure (ADHF) patients. The company was founded in 2018 and is based in Milford, Massachusetts. Reprieve Cardiovascular, Inc. operates as a subsidiary of CardioRenal Systems, Inc.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

ARTMS Products Inc. is a Vancouver-based company that specializes in manufacturing diagnostic imaging systems for the production and separation of medical isotopes. Founded in 2013, the company has developed the QUANTM Irradiation System, which facilitates decentralized and local production of critical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. ARTMS's primary offering, QUANTM99, is a system that combines hardware and consumables for the effective production of technetium-99m using medical cyclotrons. This innovative approach aims to enhance the accessibility and cost-effectiveness of medical isotopes, improving diagnostic imaging services.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

RubiconMD, Inc. is a New York-based company that provides an online platform designed to facilitate communication between primary care clinicians and specialists through its eConsult service. This platform enables primary care providers to discuss cases with top specialists, thereby improving patient care and reducing costs. In addition to eConsults, RubiconMD offers a range of services, including a continuing medical education (CME) credit program, live and on-demand CME webinars, and RubiconRx, a clinical pharmacy platform that supports medication access for patients. The company also provides integration services for electronic health records, onboarding and implementation support, and clinician engagement. Founded in 2013, RubiconMD serves a diverse clientele that includes employers, community health centers, correctional health clinicians, health plans, health systems, and direct primary care practices.

Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.

Four Points Innovation supports Duke R&D projects throughout preclinical stages of drug discovery and development. Beginning approximately in March 2020, Duke researchers can submit proposals on projects for consideration by a Four Points Innovation committee comprised of scientific leadership representing Duke and Deerfield.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Contessa Health, Inc., based in Nashville, Tennessee, specializes in home hospitalization programs designed to enhance patient care while managing episodic risk. The company is recognized as a pioneer in Home Recovery Care, a risk-based model that integrates essential components of inpatient hospital care within patients' homes. Contessa employs a proprietary health informatics platform to support this model, ensuring that care is safe, affordable, and effective in improving patient outcomes. Additionally, Contessa offers solutions such as ContessaCare, which empowers healthcare providers to deliver hospital-level care at home, and ContradoClaim, a claims analytics tool that assists partners in managing prospective payments. The company also provides bundled payment managed services, enabling health plans and systems to optimize their care delivery without the need for hospital admissions. Contessa Health was founded in 2015 and continues to lead innovations in home-based healthcare.

TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.

Trinity Biotech is engaged in the development, manufacturing, and marketing of medical diagnostic products for clinical laboratories and point-of-care settings. The company offers a wide range of diagnostic tests and instrumentation that detect infectious diseases, sexually transmitted infections, autoimmune disorders, and conditions related to diabetes and liver health. With a portfolio of over 400 products, it employs various diagnostic formats, including immunofluorescence assays and enzyme-linked immunosorbent assays. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors. Its products are marketed under several brand names, including Recombigen and Unigold, and are sold through a direct sales force and a network of independent distributors. The company serves a diverse clientele, including public health facilities, hospitals, and clinical laboratories. Founded in 1992 and headquartered in Bray, Ireland, Trinity Biotech has established a strong presence in the diagnostic market across regions including the Americas, Europe, Africa, and Asia.

Pinnacle Hill is a collaboration between the University of North Carolina at Chapel Hill and Deerfield Management, focused on discovering new medicines to address significant unmet medical needs. The company develops therapeutic medical drugs targeting diseases such as multiple myeloma and Angelman syndrome. Its innovative approach aims to replace or reactivate the faulty UBE3A gene in affected nerve cells, providing healthcare professionals with new treatment options for patients facing life-threatening conditions. Deerfield Management contributes up to $65 million in targeted funding and offers drug development expertise to enhance the promising therapeutic research at UNC-Chapel Hill.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Concert Genetics, Inc. is a healthcare information technology company based in Franklin, Tennessee, that specializes in simplifying and unifying genetic testing processes for various stakeholders, including hospitals, health systems, patients, and clinicians. The company offers software and analytical tools designed to streamline genetic test selection, ordering, payment, and management operations. Its services include claim-to-test matching, medical policy support, utilization management, and business intelligence reports, catering to health plans, hospitals, laboratories, and regulatory agencies. By providing a comprehensive platform, Concert Genetics helps physicians access the necessary information to efficiently order genetic tests for diagnosing over 2,000 diseases, thereby enhancing clinical outcomes. The company also offers the Concert Genetics Benefit Program, which facilitates access to clinically appropriate genetic testing while improving payment integrity and reducing administrative burdens. Founded in 2010 and originally known as NextGxDx Inc., Concert Genetics rebranded in 2017 and has established a strategic partnership with Trapelo Health.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Adeptus Health is a healthcare organization focused on providing emergency medical care through a network of freestanding emergency rooms and strategic partnerships with various healthcare providers. The organization operates First Choice Emergency Room in Texas, a network of independent facilities equipped with advanced diagnostic radiology technology, including CT scans, ultrasounds, and digital X-rays, as well as on-site laboratories staffed by physicians and emergency-trained registered nurses. In Colorado, Adeptus collaborates with the University of Colorado Health to operate UCHealth Emergency Rooms. Additionally, in Arizona, the organization partners with Dignity Health to manage Dignity Health Arizona General Hospital and freestanding emergency rooms. In Louisiana, Adeptus has established a partnership with Ochsner Health System, further expanding its reach and accessibility in emergency medical care.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Endologix, Inc. is a medical device company that specializes in the development and manufacturing of minimally invasive treatments for abdominal aortic aneurysms (AAA). The company's product portfolio includes several endovascular aneurysm repair (EVAR) systems, such as the AFX endovascular AAA system, which features a minimally invasive delivery mechanism, and the VELA Proximal Endograft, designed for specific aortic neck anatomies. Additionally, Endologix offers the Ovation abdominal stent graft system and the Nellix endovascular aneurysm sealing (EVAS) system, which effectively seals aneurysms while ensuring adequate blood flow to the legs. The company also provides extensions and accessories to customize and facilitate the delivery of its devices. Endologix markets its products through a direct sales force and a network of third-party distributors and agents. Established in 1992 and based in Irvine, California, Endologix has evolved from its original name, Radiance Medical Systems, Inc., to focus solely on addressing critical aortic-related health issues.

Chondrial Therapeutics LLC is a clinical-stage biotechnology company based in Indianapolis, Indiana, founded in 2013. The company specializes in discovering and developing orphan drugs aimed at treating rare mitochondrial diseases, with a particular focus on Friedreich’s Ataxia. Through its commitment to scientific research, Chondrial Therapeutics seeks to advance innovative therapies for patients affected by these challenging conditions.

Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiorenal diseases. Headquartered in Fremont, California, Ardelyx's lead product candidate, tenapanor, has successfully completed Phase 3 clinical trials for treating irritable bowel syndrome with constipation and is also in Phase 3 trials for managing hyperphosphatemia in end-stage renal disease patients undergoing dialysis. The company is advancing RDX013, a small molecule potassium secretagogue, aimed at treating hyperkalemia. Ardelyx is also developing RDX5791, an oral NHE3 sodium transport inhibitor targeting constipation-predominant irritable bowel syndrome and excess dietary sodium absorption, currently in Phase 2 trials. Additionally, RDX002 and RDX009, which inhibit phosphate absorption and target type 2 diabetes, respectively, are in preclinical development. Ardelyx emphasizes non-systemic oral therapeutics that minimize side effects while effectively addressing metabolic disorders. Since its founding in 2007, the company has secured significant funding to support its research and development efforts.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

Advantia Health, LLC is a healthcare delivery company focused on providing comprehensive services to women and their families. Founded in 2014 and headquartered in Arlington, Virginia, Advantia Health offers a range of services including obstetrics, gynecology, primary care, and mental wellness, with additional locations in Virginia, Maryland, Illinois, and Missouri. The company emphasizes high-quality and efficient care through the use of technology and well-designed outpatient facilities. Advantia Health also provides telehealth services, allowing patients to connect with healthcare providers via a web and mobile application, ensuring timely access to the right care in the appropriate setting.

Hallux Inc. is a clinical-stage pharmaceutical company dedicated to the research and development of a novel micro-insert designed for subungual delivery to treat distal lateral subungual onychomycosis. Founded in 2012 and based in Laguna Hills, California, Hallux focuses on a biodegradable topical dosage form that delivers high concentrations of terbinafine hydrochloride directly to the site of infection. This targeted approach aims to improve treatment efficacy while minimizing systemic exposure, thus reducing the risk of liver complications and drug interactions. Initial pilot studies have shown promising results, indicating that the subungual treatment procedure is both safe and well-tolerated. Hallux's innovative technology represents a significant advancement in the treatment of onychomycosis and other nail disorders.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

RedBrick Health is a health engagement and behavior-based technology company based in Minneapolis, founded in 2006. The company offers innovative solutions to address rising healthcare costs by combining behavior-based health financing with personalized programs and independent advocacy. RedBrick Health assists employers, health plans, health systems, and accountable care organizations in enhancing consumer health outcomes. Their technology-enabled enterprise platform leverages advanced behavior design and data analytics to promote healthier behaviors and informed healthcare decisions. By creating effective consumer experiences, RedBrick Health helps organizations optimize their health and wellness initiatives, ultimately improving the performance of population health and well-being programs.

NeoChord, Inc. is a medical technology company that specializes in developing devices to address degenerative mitral valve disease (DMR), a condition that can lead to serious complications such as atrial fibrillation and congestive heart failure. The company's flagship product is the NeoChord Artificial Chordae Delivery System, a disposable device designed to repair damaged heart chordae through a small incision while the heart continues to beat. This innovative approach allows for mitral valve repair to be performed via a 2 to 3-inch incision between the ribs, significantly less invasive than traditional methods that require larger incisions and the use of heart-lung machines. Founded in 2007, NeoChord is headquartered in St. Louis Park, Minnesota.

Trinity Biotech is engaged in the development, manufacturing, and marketing of medical diagnostic products for clinical laboratories and point-of-care settings. The company offers a wide range of diagnostic tests and instrumentation that detect infectious diseases, sexually transmitted infections, autoimmune disorders, and conditions related to diabetes and liver health. With a portfolio of over 400 products, it employs various diagnostic formats, including immunofluorescence assays and enzyme-linked immunosorbent assays. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors. Its products are marketed under several brand names, including Recombigen and Unigold, and are sold through a direct sales force and a network of independent distributors. The company serves a diverse clientele, including public health facilities, hospitals, and clinical laboratories. Founded in 1992 and headquartered in Bray, Ireland, Trinity Biotech has established a strong presence in the diagnostic market across regions including the Americas, Europe, Africa, and Asia.

Breathe Technologies, Inc. develops and manufactures innovative medical technologies aimed at treating respiratory insufficiency diseases. Founded in 2005 and based in Irvine, California, the company specializes in non-invasive open ventilation systems designed for patients suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Its lightweight mechanical ventilators are equipped with features that support continuous ventilation while promoting patient mobility, making them suitable for use in various healthcare settings, including intensive care units and pulmonary rehabilitation. Breathe Technologies operates as a subsidiary of Hill-Rom, Inc., focusing on enhancing respiratory care both in hospital environments and at home.

MedAvail operates as a technology-enabled pharmacy company that integrates automated pharmacy services within clinics and other healthcare settings using its proprietary technology. The company offers comprehensive services through its robotic dispensing platform, known as the MedAvail MedCenter, alongside home delivery options. Additionally, it runs SpotRx, a telehealth platform that facilitates remote pharmacist consultations through on-site dispensing kiosks, complemented by home delivery services. MedAvail is headquartered in Mississauga, Canada.

SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.

SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.

Epion Health, Inc. is a provider of mobile health applications and content, utilizing a cloud-based application and content management solution. Founded in 2011 and headquartered in Roseland, New Jersey, the company focuses on enhancing patient engagement by offering tools that allow patients to access health information on their smartphones and other mobile devices. This enables them to better understand their health and prepare for medical visits. Additionally, Epion Health provides physicians with access to essential health information and pre-loaded medical applications, including drug references and dosage calculators, which support improved patient care and communication within the healthcare continuum.

Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.

iCAD, Inc. (iCAD) is a provider of image analysis and workflow solutions that enable radiologists and other healthcare professionals to serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a range of high-performance, expandable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT)). iCAD's solutions aid in the early detection of the prevalent cancers including breast, prostate and colon cancer. The Company's CAD systems include algorithm and other technology together with standard computer and display equipment. CAD systems for the film-based analog mammography market also include a radiographic film digitizer, either manufactured by the Company or others for the digitization of film-based medical images. !

WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.

Insulet Corporation is a medical device company that develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes. The company's primary product, the Omnipod System, consists of a disposable, tubeless insulin infusion device that adheres to the body for up to three days, along with a wireless personal diabetes manager for monitoring and control. Insulet markets its products through independent distributors and pharmacy channels, as well as directly to patients in the United States, Canada, Europe, and the Middle East. Founded in 2000, Insulet is headquartered in Acton, Massachusetts, and aims to enhance the quality of life for people managing diabetes through innovative technology.

NxStage Medical, Inc. is a medical technology company that specializes in developing, manufacturing, and marketing products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. Its flagship product, the NxStage System One, is a portable hemodialysis system primarily used for home dialysis. The company also offers the PureFlow SL, an integrated unit for water purification and dialysate production, along with chronic cartridges that support flexible dialysis options at home. Additionally, NxStage provides a telehealth platform called Nx2me Connected Health for managing home hemodialysis treatments and patient data. In its product line, NxStage includes bloodlines, needles, and dialysis fluids, and it operates dialysis centers to deliver direct patient care. Founded in 1998 and based in Lawrence, Massachusetts, NxStage Medical operates as a subsidiary of Fresenius Medical Care Holdings, Inc.

Third Wave Technologies, Inc. is involved in the development and marketing of molecular diagnostic products that cater to a range of DNA and RNA analysis applications. The company provides innovative solutions for physicians and researchers focused on disease analysis and treatment. Its proprietary Invader chemistry is utilized across several segments, including women's health, infectious diseases, genetics, pharmacogenetics, and oncology. Third Wave offers in vitro diagnostic devices and analyte-specific reagents that enable laboratories to perform various assays, such as hepatitis C virus genotyping and testing for inherited disorders and genetic mutations. Additionally, the company develops products for research and agricultural biotechnology markets. Its clientele comprises clinical laboratories, pharmaceutical and biotechnology companies, academic institutions, and healthcare providers. Third Wave employs direct sales strategies and collaborative partnerships to market its products in the United States and Europe. Founded in 1993, Third Wave Technologies is headquartered in Madison, Wisconsin, and is currently a subsidiary of Hologic Inc.

Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.

Breathe Technologies, Inc. develops and manufactures innovative medical technologies aimed at treating respiratory insufficiency diseases. Founded in 2005 and based in Irvine, California, the company specializes in non-invasive open ventilation systems designed for patients suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Its lightweight mechanical ventilators are equipped with features that support continuous ventilation while promoting patient mobility, making them suitable for use in various healthcare settings, including intensive care units and pulmonary rehabilitation. Breathe Technologies operates as a subsidiary of Hill-Rom, Inc., focusing on enhancing respiratory care both in hospital environments and at home.